An Open, Randomized,Positive Control, Multicenter Phase III Clinical Study of SHR A1904 for Injection Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patients With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 17 Dec 2024
At a glance
- Drugs SHR-A1904 (Primary) ; Docetaxel; Irinotecan; Paclitaxel
 - Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
 - Focus Registrational; Therapeutic Use
 - Sponsors Shanghai Hengrui Pharmaceutical
 
Most Recent Events
- 17 Dec 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health
 - 12 Dec 2024 Status changed from not yet recruiting to recruiting.
 - 24 Oct 2024 New trial record